Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Shan Dong Kexing Bioproducts Co's Revenue for the
three
months ended in Mar. 2026 was ¥281 Mil. Shan Dong Kexing Bioproducts Co's average Accounts Receivable for the
three
months ended in Mar. 2026 was ¥584 Mil.
Hence, Shan Dong Kexing Bioproducts Co's Receivables Turnover for the
three
months ended in Mar. 2026 was 0.48.
Shan Dong Kexing Bioproducts Co (SHSE:688136) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Shan Dong Kexing Bioproducts Co Receivables Turnover Related Terms
Shan Dong Kexing Bioproducts Co Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shan Dong Kexing Bioproducts Co Receivables Turnover Chart
SHSE:688136 vs VRTX, REGN, RVMD: Receivables Turnover Comparison
For the Biotechnology subindustry, Shan Dong Kexing Bioproducts Co's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shan Dong Kexing Bioproducts Co Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shan Dong Kexing Bioproducts Co's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Shan Dong Kexing Bioproducts Co's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shan Dong Kexing Bioproducts Co (SHSE:688136) has a Receivables Turnover of 0.48 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Shan Dong Kexing Bioproducts Co and its competitors. According to the industry distribution chart, Shan Dong Kexing Bioproducts Co ranks #679 out of 841 companies in the Biotechnology industry, placing it in the top 80.7%.
Is Shan Dong Kexing Bioproducts Co's Receivables Turnover too high?
Shan Dong Kexing Bioproducts Co's current Receivables Turnover is 0.48. The Biotechnology industry median Receivables Turnover is 5.27. Shan Dong Kexing Bioproducts Co's value of 0.48 is 90.9% below this industry median. Based on the distribution chart, Shan Dong Kexing Bioproducts Co ranks #679 out of 841 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Shan Dong Kexing Bioproducts Co has a GF Score™ of 46/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shan Dong Kexing Bioproducts Co's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shan Dong Kexing Bioproducts Co ranks #679 out of 841 companies for Receivables Turnover. This places Shan Dong Kexing Bioproducts Co in the lower half of its industry. The industry median Receivables Turnover is 5.27. Shan Dong Kexing Bioproducts Co's value of 0.48 is 90.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.27, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shan Dong Kexing Bioproducts Co's current Receivables Turnover of 0.48 is 90.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Shan Dong Kexing Bioproducts Co and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shan Dong Kexing Bioproducts Co's current Receivables Turnover is 0.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shan Dong Kexing Bioproducts Co stock overvalued right now?
Based on GuruFocus' analysis, Shan Dong Kexing Bioproducts Co (SHSE:688136) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥24.36, compared to a current price of ¥20.29 — trading 16.7% below its estimated fair value. The current Receivables Turnover is 0.48 and 90.9% below the Biotechnology industry median of 5.27. Shan Dong Kexing Bioproducts Co's overall GF Score™ is 46/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Shan Dong Kexing Bioproducts Co (SHSE:688136), the current Receivables Turnover is 0.48 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shan Dong Kexing Bioproducts Co (SHSE:688136) Overvalued in 2026?
Based on GuruFocus' analysis, Shan Dong Kexing Bioproducts Co stock appears to be undervalued.
The current stock price of ¥20.29 is trading 16.7% below its estimated GF Value™ of ¥24.36.
GuruFocus considers Shan Dong Kexing Bioproducts Co to be Modestly Undervalued.
Key valuation signals for SHSE:688136:
Receivables Turnover: 0.48
GF Value™: ¥24.36 vs. price of ¥20.29 (16.7% below fair value)
Industry Position: 90.9% below the Biotechnology median (#679 of 841)
No single metric tells the full story. See the SHSE:688136 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shan Dong Kexing Bioproducts Co Ltd formerly Kexing Biopharmaceutical Co Ltd is an innovative biopharmaceutical company. It is engaged in the production and sales of recombinant protein drugs and probiotics. The company use the drugs in the fields of antiviral, hematology, tumor and immunity, and degenerative diseases.
46GF Score
Get the complete analysis for SHSE:688136
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688136 has been successfully added to your 
